it’s internship application season!

Looking for a life science summer internship?

Apply for SPRINT Internships now (Jan & Feb 2023)

Looking for internship funding? Apply for CTNext’s Talent Bridge (TTB) program below! 

TTB deadline is January 20th, 2023

EXCLUSIVE DISCOUNTS

New England Edge offers you substantial savings on the products and services you use the most.

Explore Offers

JOIN BIOCT

A diverse community of innovators committed to the growth and sustainability of our bioscience community.

Join Now

Stay Informed

Keep up-to-date on the latest news, events, BioCT happenings, and more.

Sign Me Up

CAREER CENTER

Your source for today’s talent, job opportunities and career development.

Career Center

BioCT is the voice of Connecticut’s bioscience industry.

BioCT’s mission is to catalyze and accelerate growth in the life sciences with the goal of improving human health, by fostering a rich, innovative ecosystem and promoting Connecticut as a preferred destination for life science exploration and innovation.

Upcoming Events

BIO CEO & Investor Conference

Now in its 25th year, the BIO CEO & Investor Conference fuels the biotech industry as a premier event for C-Suite leaders and the investor...

2
Academic Bioscience R&D Investment
2
Patent Activity
721
NIH Funding in 2020
4
Bioscience Venture Capital
4
Most Innovative State
5
Science & Engineering Doctorates
6
Quality of Life
1
Most Diverse State in New England

BioCT is grateful for the support of our partners & sponsors.

Your exclusive member benefits.

We’ve partnered with MassBio to bring you an even-bigger purchasing program featuring the supplier discounts their members enjoy.
Save big on everything you need, from travel to office products to lab supplies and more.

Click for Discounts

Newsroom

The Roundup – February 2, 2023

View this email in your browser February 2, 2023 Connecticut Innovations (CI) announced that it invested $10 million in early-stage companies and fund of funds during the...

FDA accepts NDA re Jardiance® for kidney disease

Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets. The tablets are being investigated as...